Compare HNNA & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | HNNA | TVGN |
|---|---|---|
| Founded | 1989 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Blank Checks |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.2M | 66.8M |
| IPO Year | N/A | N/A |
| Metric | HNNA | TVGN |
|---|---|---|
| Price | $10.54 | $0.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 26.7K | ★ 645.2K |
| Earning Date | 02-12-2026 | 11-14-2025 |
| Dividend Yield | ★ 5.32% | N/A |
| EPS Growth | ★ 38.04 | N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $35,538,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.14 | ★ N/A |
| Revenue Growth | ★ 19.88 | N/A |
| 52 Week Low | $8.43 | $0.30 |
| 52 Week High | $13.19 | $1.92 |
| Indicator | HNNA | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 65.34 | 48.82 |
| Support Level | $10.01 | $0.32 |
| Resistance Level | $10.48 | $0.34 |
| Average True Range (ATR) | 0.28 | 0.03 |
| MACD | 0.09 | 0.00 |
| Stochastic Oscillator | 95.08 | 50.31 |
Hennessy Advisors Inc is an investment management company that manages and markets open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, multi-asset sectors, specialty products, and fixed income products. The company earns revenues mainly from investment advisory services and secondarily from shareholder services. Advisory services include managing each fund's portfolio in line with its investment objectives, monitoring compliance and performance, overseeing sub-advisors and other service providers, and handling marketing, distribution, and regulatory reporting. Shareholder services cover investor support and coordination with the fund service provider, with all related fees based on the funds' average daily net asset values.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.